D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 86 Citations 31,423 633 World Ranking 7265 National Ranking 14

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Disease

Evangelos Terpos mainly investigates Internal medicine, Multiple myeloma, Bone disease, Bortezomib and Surgery. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Oncology. His Multiple myeloma study incorporates themes from Cancer research, Clinical trial, Zoledronic acid, Radiology and Osteonecrosis of the jaw.

His study explores the link between Bone disease and topics such as Osteolysis that cross with problems in N-terminal telopeptide. He interconnects Melphalan and Lenalidomide, Dexamethasone in the investigation of issues within Bortezomib. His studies deal with areas such as Bisphosphonate and Thalidomide as well as Surgery.

His most cited work include:

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders (756 citations)

What are the main themes of his work throughout his whole career to date?

Evangelos Terpos mostly deals with Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery. The study incorporates disciplines such as Gastroenterology and Endocrinology in addition to Internal medicine. His Multiple myeloma research includes themes of Cancer research, Bone disease and Bone marrow.

His work in the fields of Oncology, such as Zoledronic acid, intersects with other areas such as In patient. His Bortezomib research incorporates themes from Proteasome inhibitor, Pharmacology and Renal function. His research in Surgery tackles topics such as Urology which are related to areas like Creatinine.

He most often published in these fields:

  • Internal medicine (61.50%)
  • Multiple myeloma (53.41%)
  • Oncology (22.89%)

What were the highlights of his more recent work (between 2017-2021)?

  • Multiple myeloma (53.41%)
  • Internal medicine (61.50%)
  • Oncology (22.89%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Multiple myeloma, Internal medicine, Oncology, Bortezomib and Lenalidomide. His Multiple myeloma research incorporates elements of Cancer research, Clinical trial, Bone disease and Bone marrow. His research on Clinical trial also deals with topics like

  • Intensive care medicine together with MEDLINE,
  • Disease which intersects with area such as Immunology.

Hematology is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine. His biological study spans a wide range of topics, including Ixazomib, Relapsed refractory, Refractory and Pomalidomide. His work carried out in the field of Lenalidomide brings together such families of science as Prospective cohort study, Adverse effect and Thalidomide.

Between 2017 and 2021, his most popular works were:

  • Hematological findings and complications of COVID-19. (540 citations)
  • Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study (139 citations)
  • Pathogenesis of bone disease in multiple myeloma: from bench to bedside. (100 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary areas of study are Internal medicine, Multiple myeloma, Oncology, Bortezomib and Clinical trial. In his work, AL amyloidosis is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine. The Multiple myeloma study combines topics in areas such as Minimal residual disease, Bone disease, Disease and Intensive care medicine.

In his research, Cancer research is intimately related to RANKL, which falls under the overarching field of Bone disease. Evangelos Terpos has researched Bortezomib in several fields, including Refractory and Transplantation. His Clinical trial research is multidisciplinary, incorporating perspectives in Salvage therapy and Randomized controlled trial.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn.
Blood (2005)

1087 Citations

Hematological findings and complications of COVID-19.

Evangelos Terpos;Ioannis Ntanasis‐Stathopoulos;Ismail Elalamy;Efstathios Kastritis.
American Journal of Hematology (2020)

795 Citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)

567 Citations

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Blood (2015)

504 Citations

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

M. A. Dimopoulos;E. Kastritis;C. Bamia;I. Melakopoulos.
Annals of Oncology (2008)

465 Citations

Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

Evangelos Terpos;Evangelos Terpos;Richard Szydlo;Richard Szydlo;Jane F. Apperley;Jane F. Apperley;Evdoxia Hatjiharissi;Evdoxia Hatjiharissi.
Blood (2003)

445 Citations

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

Meletios A. Dimopoulos;Evangelos Terpos;Asher Chanan-Khan;Nelson Leung.
Journal of Clinical Oncology (2010)

444 Citations

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid

Meletios A Dimopoulos;Efstathios Kastritis;Athanasios Anagnostopoulos;Ioannis Melakopoulos.
Haematologica (2006)

427 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Evangelos Terpos

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 205

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 181

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 178

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 158

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 147

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 135

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 125

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 122

Nelson Leung

Nelson Leung

Mayo Clinic

Publications: 116

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 115

Francis K. Buadi

Francis K. Buadi

Mayo Clinic

Publications: 113

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 108

David Dingli

David Dingli

Mayo Clinic

Publications: 106

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 105

Michele Cavo

Michele Cavo

University of Bologna

Publications: 102

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 100

Something went wrong. Please try again later.